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The abundance, morphology, and functional properties of mitochondria decay in skeletal muscle during the process of ageing.
Although the precise mechanisms remain to be elucidated, these mechanisms include decreased mitochondrial DNA (mtDNA)
repair and mitochondrial biogenesis. Mitochondria possess their own protection system to repair mtDNA damage, which leads to
defects of mtDNA-encoded gene expression and respiratory chain complex enzymes. However, mtDNA mutations have shown to
be accumulated with age in skeletal muscle. When damaged mitochondria are eliminated by autophagy, mitochondrial biogenesis
plays an important role in sustaining energy production and physiological homeostasis. The capacity for mitochondrial biogenesis
has shown to decrease with age in skeletal muscle, contributing to progressive mitochondrial deﬁciency. Understanding how
these endogenous systems adapt to altered physiological conditions during the process of ageing will provide a valuable insight
into the underlying mechanisms that regulate cellular homeostasis. Here we will summarize the current knowledge about the
molecular mechanisms responsible for age-associated mitochondrial deﬁciency in skeletal muscle. In particular, recent ﬁndings on
the role of mtDNA repair and mitochondrial biogenesis in maintaining mitochondrial functionality in aged skeletal muscle will be
highlighted.
1.Introduction
Mitochondria are ubiquitous membrane-bound organelles
that are a deﬁning and unique feature of the eukaryotic
cell [1]. Mitochondria produce about 90% of the energy
necessary for cellular function via oxidative phosphorylation
(OXPHOS)[2].Additionally,mitochondriaplaycentralroles
in metabolism, signaling, and programmed cell death [3].
Mitochondrial deﬁciency has been shown in neuromuscular
diseases, neurodegenerative diseases, type 2 diabetes, ageing,
and sarcopenia [4–8]. During the process of ageing, the
abundance, morphology, and functional properties of mito-
chondria decay in several tissues including skeletal muscle
[9–12]. Among all cell types, the skeletal muscle possesses
the unique ability to increase metabolic rate nearly 100-
fold during the transition form a basal resting state to
near-maximal contractile activity [11] .T h u s ,i ti se a s yt o
assume that skeletal muscle is profoundly aﬀected by age-
associated mitochondrial deﬁciency. Despite age-associated
mitochondrial deﬁciency being extensively investigated, the
precise mechanisms remain to be elucidated. However,
these mechanisms include at least decreased mitochondrial
DNA (mtDNA) repair, defective mitochondrial removal, and
decreased mitochondrial biogenesis, ultimately resulting in
decreased function of the whole organelle. The mitochon-
drial theory of ageing [13] is thought to be one of the most
popular theories of ageing [14]. The mitochondrial theory
of aging can be summarized as follows: reactive oxygen
species (ROS) emanating from mitochondrial OXPHOS
are responsible for the accumulation of somatic mtDNA
mutations. These mutations are postulated to result in the
production of faulty OXPHOS components, leading to the
production of still more ROS. Enhanced mitochondrial ROS
production and damage can subsequently lead to a “vicious2 Journal of Aging Research
cycle” of exponentially increasing levels of mtDNA damage
and oxidative stress in the cell [15]. To prevent deleterious
eﬀectsin organelle, mtDNA damage is balanced by their own
repair system [16]. The changes in the ﬁdelity and eﬃcacy of
mtDNA repair may lead to mtDNA damage accumulation
during the process of ageing [16]. As damaged mitochondria
are eliminated by autophagy (termed mitophagy), mito-
chondrial biogenesis plays an important role in sustaining
energy production and physiological homeostasis in the cell
[12].Thecapacityformitochondrialbiogenesishasshownto
decrease with age, contributing to progressive mitochondrial
deﬁciency [17]. At the molecular level, several transcription
factors, nuclear receptors, and coactivators are involved in
the activation and regulation of mitochondrial biogenesis.
Accumulatingevidencesuggestthatperoxisomeproliferator-
activated receptor gamma coactivator-1 alpha (PGC-1α)
plays a key role in mitochondrial biogenesis [1, 3, 18, 19].
PGC-1α works in concert with several transcription factors
and nuclear receptors to activate expression of a broad
set of mitochondrial genes [1]. The activity of PGC-1α is
regulatedbyavarietyofposttranslationalmodiﬁcationssuch
as phosphorylation and acetylation [1, 3, 18, 20]. These
modiﬁcations have assumed to be an important mechanism
that could regulate PGC-1α transcriptional activity [3,
18]. Understanding how these endogenous systems adapt
to altered physiological conditions during the process of
ageing will provide a valuable insight into the underlying
mechanisms that regulate cellular homeostasis [21]. Here we
will summarize the current knowledge about the molecular
mechanisms responsible for age-associated mitochondrial
deﬁciency in skeletal muscle. In particular, recent ﬁndings
on the role of mtDNA repair and mitochondrial biogenesis
in maintaining mitochondrial functionality in aged skeletal
muscle will be highlighted.
2. Mitochondrial DNA Mutations in Aged
Skeletal Muscle
Numerous studies have shown that mtDNA accumulates
oxidative damage in an age-dependent manner in a variety
of tissue [22]. The mutations include deletions, point muta-
tions, and duplications that have been found to accumulate
in mtDNA in several tissues of various species during
the process of ageing [7]. It has been estimated that the
proportions of mutated mtDNA in ageing human tissues
rarely exceed 1% [22]. How this apparent low level mutation
can be functionally relevant in ageing continues to be topics
of vigorous debate [22]. In the case of aged skeletal muscle,
mtDNA deletion mutations are at low abundance (<0.1%)
when calculated against the total mitochondrial pool in
tissue homogenates [23]. When, however, discrete myoﬁbers
areanalyzed,theabundanceofmtDNAdeletionmutationsis
inversely proportional to the number of myoﬁbers analyzed
[24]. In support of this, mtDNA deletion mutations are
not distributed homogeneously throughout a tissue, but
ampliﬁed focally within a subset of myoﬁbers, appearing as
a segmental pattern along the length of myoﬁbers and as a
mosaic distribution between myoﬁbers [25]. Mitochondria
possess their own DNA repair system to protect cells from
mutations. Although the DNA repair mechanisms in mito-
chondria are not as well known as those taking place in
the nucleus, the knowledge on mtDNA repair functions
is increasing [26]. It was reported an expanded range of
mitochondrial DNA repair systems such as base excision
repair (BER) including single-nucleotide and long-patch
BER, double-strand break repair (homologous recombina-
tion and nonhomologous end-joining), and direct repair
[16]. Here we provide information on mtDNA mutations
in aged skeletal muscle and mtDNA repair system. We
discusstheageingeﬀectsonmtDNArepairactivityinskeletal
muscle.
Mitochondria possess their own DNA. Each mitochon-
drion consists of 16,569 base pairs which encode 37 genes
encoding 13 genes that are required for OXPHOS, 22
transfer RNAs, and 2 ribosomal RNAs [27]. Despite the
fact that mtDNA comprises only 1–3% of genetic material
in animal cells, several lines of evidence suggest that its
contribution to cellular physiology could be much greater
than would be expected from its size alone. For instance, (a)
it mutates at higher rates than nuclear DNA; (b) it encodes
either polypeptides of electron transport system (ETS) or
components required for their synthesis such as tRNAs and
rRNAs, and therefore, any coding mutations in mtDNA will
aﬀect the ETS as a whole; this could aﬀect both the assembly
and function of the products of numerous nuclear genes in
ETS complexes; (c) defects in the ETS can have pleiotropic
eﬀects because they aﬀect cellular energetics as a whole [28].
Abnormalities of mitochondrial ETS enzymatic activities
havebeenidentiﬁedusingahistochemicalmethod.Activities
of two complexes of the ETS are commonly analyzed:
complex II (succinate dehydrogenase; SDH) and complex
IV (cytochrome c oxidase; COX). Abnormal myoﬁbers are
characterized by negative for COX and hyperreactive for
SDH [25]. These ﬁbers have been termed “ragged-red” ﬁbers
(RRFs), which display a granular, mottled red appearance
with the modiﬁed Gomori trichrome stain [29]. RRF was
initially characterized in human mitochondrial myopathy
diseases that are neuromuscular disorders associated with
defects of the mitochondrial genome [30]. The frequency
of RRFs in old humans (61 to 77 years of age) was much
higher than that in young humans (21 to 31 years of
age) (0.33 versus 0.02%) [31]. In animal, the frequency of
myoﬁbers exhibiting ETS abnormalities in old (34 years)
and young adult (11 years) rhesus monkeys was 2.41 and
0.16%, respectively [32]. Interestingly, it could be estimated,
however, that up to 60% of the myoﬁbers display ETS
abnormalitiesintheoldanimalcomparedto4%intheyoung
adultanimal,whenextrapolatingthedatatotheentirelength
of the myoﬁber [32].
The ETS abnormalities observed in aged skeletal muscle
appear to correlate closely with mtDNA deletion mutations.
IthasbeenreportedthatmtDNA4977-bpdeletioncorrelates
with respiratory chain enzyme activities in ageing human
skeletalmuscles[33].Thisisthemostfrequentandbestchar-
acterized age-associated mtDNA deletion mutation, called
the “common deletion.” This deletion is especially frequent
in well-diﬀerentiated cells with a low mitotic rate, such asJournal of Aging Research 3
brain and muscle cells [34]. Cao et al. [35] determined the
mitochondrial genotype of aged rat myoﬁbers exhibiting
ETS abnormalities using histochemical analysis and laser-
capture microdissection combined with PCR. Large mtDNA
deletion (4.4–9.7kb) was detected in all ETS abnormal
myoﬁbers. The deleted mtDNA genomes were detected only
in the regions of the myoﬁbers with ETS abnormalities;
adjacent phenotypically normal portions of the same ﬁber
contained wild-type mtDNA. Additionally, identical mtDNA
deletion mutations were found within diﬀerent sections of
the same abnormal region. They suggest that large deletion
mutations are associated with ETS abnormalities in aged
rat skeletal muscle and that a clonal expansion of deleted
mitochondrial genome occurs in ETS abnormal regions
of myoﬁbers. Similarly, Herbst et al. [36] reported that
aged myoﬁbers possessed segmental, clonal intracellular
expansions of unique somatically derived mtDNA deletion
mutations. When the mutation abundance surpassed 90%
of the total mitochondrial genomes, the myoﬁber lost
COX activity and exhibited an increase in SDH activity.
These ﬁndings support the idea that mutated mtDNA may
have replicative advantages over normal DNA, resulting,
in turn, in preferential propagation (clonal expansion) of
defective mitochondria. Augmented replication of mutated
mtDNA remains, however, unexplained. It is hypothesized
that deleted DNA replicates faster due to its shorter length,
although this explanation cannot be applied to DNA with
point mutations [37]. Besides the mitochondrial enzymatic
abnormalities, some myoﬁbers displayed abnormal mor-
phology such as ﬁbers splitting, atrophy, and breakage.
Therefore, it is speculated that the somatic generation and
subsequent intracellular accumulation of mtDNA deletion
mutations may contribute to the age-dependent loss of
myoﬁbers and sarcopenia [36].
Besides deletion mutations, point mutations, and dupli-
cations also occur in mtDNA of aged skeletal muscle.
Zhang et al. [38] reported the age-related mutation A
to G at nucleotide potion 3243 on mtDNA in skeletal
muscle. Munscher et al. [39] reported the A8344G transition
mutation in the tRNALys gene of mtDNA, characteristic
for the maternally inherited MERRF syndrome (myoclonic
epilepsy with ragged red ﬁbers) in extraocular muscle from
individuals aged 67–89 years old. The amount of mutated
from total mtDNA was estimated in extraocular muscle
of 2 individuals of 74 and 89 years to 2.0 and 2.4%,
respectively. Fayet et al. [40]r e p o r t e dt h a th i g hl e v e l so f
clonally expanded point mutations were identiﬁed in eight
cytochrome-c-oxidase-deﬁcient myoﬁbres from individuals,
without muscle disease, aged 69–82 years but in none of
the normal ones. They included the previously described
pathogenic tRNALeu (UUR) A3243G and tRNALys A8344G
mutations and three original mutations: tRNAMet T4460C,
tRNAMet G4421A, and a 3-bp deletion in the tRNALeu
(UUR) gene. Wang et al. [41] reported that muscle-speciﬁc
mutations accumulate with ageing in critical human mtDNA
control sites for replication. Most of 26 individuals 53 to
92 years old, without a known history of neuromuscular
disease, exhibited at mtDNA replication control sites in
skeletalmuscleanaccumulationoftwonewpointmutations,
that is, A189G and T408A, which were absent or marginally
present in 19 individuals younger than 34 years. These two
mutations were not found in ﬁbroblasts from 22 subjects 64
to 101 years of age (T408A), or were present only in three
subjects in very low amounts (A189G). They suggest that
the striking tissue speciﬁcity of the skeletal muscle mtDNA
mutations detected and their mapping at critical sites for
mtDNA replication strongly point to the involvement of a
speciﬁcmutagenicmachineryandtothefunctionalrelevance
of these mutations. Lee [42]d e t e c t e da−260bp (type I) and
a −200bp (type II) tandem duplications in the mtDNA of
muscle biopsies from aged individuals. Only one 70-year-
old subject was found to harbour the type I and 28 out
of 58 subjects had type II duplication. About 90% of the
subjects harbouring the duplicated mtDNAs also had the
4,977bp deletion. Moreover, the incidence and quantity of
the type II duplication were found to increase with age. The
proportion of the type II duplicated mtDNA in the muscle
of a 71-year-old individual was 3.1% while that of a 55-year-
old individual was only 0.78%. They suggest that the tandem
duplicationsoccuraloneorwithmtDNAdeletionsinskeletal
muscle in an age-dependent manner, and thereby cause
synergistic deleterious eﬀects on mitochondrial respiratory
chain functions in human ageing.
3. Mitochondrial DNA RepairPathway
ROS are generally regarded as being detrimental to cellu-
lar function by modifying the structure and function of
proteins, lipids, and nucleic acid. mtDNA may be more
susceptible to damage by ROS than nuclear DNA, because
of the proximity of mtDNA to the source of ROS, altered
chromatin packaging due to the lack of histones, the lack
of introns, and the compactness of its genetic information,
ineﬃcient DNA repair systems, and asymmetry of mtDNA
replication [43–45]. Consequently, mutational damage accu-
mulates more rapidly in mtDNA compared to nuclear
DNA, leading to dysfunctional and defects in the respiratory
chain [40]. Therefore, DNA repair is thought to be an
important mechanism for maintenance of genomic integrity.
Currently, it is of great interest to understand whether
the mtDNA repair mechanisms, particularly base excision
repair, play an important role in the aging process and age-
associated diseases. Mitochondrial BER (mtBER) includes
several distinct steps [26]. The ﬁrst step in single-nucleotide
mtBER is the elimination of the damaged nucleotide. The
abnormal base is removed by a DNA glycosylase, which
recognizes the modiﬁed or inappropriate base and cleaves
the N-glycosidic bond, creating an abasic site [46]. Human
mitochondria possess and several DNA glycosylases such
as uracil-DNA glycosylase, 8-oxoguanine DNA glycosylase,
MutY homolog DNA glycosylase [47]. One of the most
extensively investigated mitochondrial DNA glycosylases is
8-oxoguanine DNA glycosylase (OGG1). OGG1 is a DNA
glycosylase with AP lyase activity that recognizes and cleaves
7,8-dihydro-8-oxoguanine (8-oxoG) from DNA [48]. The
8-oxoG DNA lesion, which can mispair with adenine and
thereby introduce GC→TA transversions during replication4 Journal of Aging Research
[49], is one of the most abundant oxidative lesions which
accumulates in the mitochondria with age [50]. The remain-
ing abasic nucleotide (AP site for apurinic and apyrimidinic
site) is eliminated by a AP endonuclease (APE), which
has two major enzymatic functions: (a) cleavage of the
phosphodiester backbone 5  to AP sites, generating 3 -OH
substrates for DNA polymerases; (b) 3 -diesterase activity
speciﬁc for the 3 -dRP products generated by β-elimination
by bifunctional glycosylases, again creating 3 -OH substrates
for DNA polymerases [46]. APE1 has been described to be
themainAPendonucleaseinmammaliancells[46].Thenext
step requires DNA polymerase-mediated de novo insertion
of a single nucleotide [16]. Mammalian mitochondria posses
a single DNA polymerase, polymerase γ [51]. The ﬁnal step
requires the ligation of the remaining single-strand nick,
which is catalyzed by a DNA ligase [46]. The human DNA
ligase III gene encodes both nuclear and mitochondrial form
of ligase [52]. For details on other mtDNA repair pathways,
please refer to some excellent reviews [16, 26].
4. Effects of Ageing on mtBER Activityin
Skeletal Muscle
It has been shown that the levels of overall mtBER activity
in rat cerebral cortices gradually are decreased with age,
reaching 80% lower activity in 30-month-old rats, compared
with 17-day-old embryos [53] .T h ed e c r e a s ei no v e r a l l
mtBER activity with age appears to attribute to the decreased
expression of repair enzymes such as OGG1 and DNA
polymerase γ [53]. Another study showed a signiﬁcant
age-dependent decrease in incision activities of all three
glycosylasesincludinguracil-DNAglycosylase,8-oxoguanine
DNA glycosylase, and endonuclease III homologue in the
mitochondria of all brain regions [54]. In skeletal muscle,
several studies have investigated the activity or expression
of speciﬁc mtBER-related enzymes in aged animals [55–
58]. For example, there were no changes in the expression
levels of DNA polymerase γ (POLγA) and DNA polymerase
γ accessory subunit (POLγB) transcripts in skeletal muscle
of young (21 to 27 years of age) and older humans (65
t o7 5y e a r so fa g e )[ 55]. The expression levels of OGG1
proteinwereslightlyincreasedinfast-twitchmusclefrom36-
month-old compared to 6-month-old rats [56], suggesting
that the level of ROS production reaches a critical threshold
to produce oxidative stress since this enzyme is considered
to be a useful biomarker for assessing oxidative stress [59].
This may be a compensatory response to oxidative stress
to attenuate mtDNA damage. This hypothesis is partially
supported in previous studies. When a vector containing a
mitochondrial transport sequence upstream of the sequence
for human OGG1 was transfected into oligodendrocytes
which are extremely sensitive to oxidative stress, it promoted
an increase in mtDNA repair and a decrease in caspase-9-
dependent apoptosis after exposure of the cells to mena-
dione, a soluble form of vitamin K, which is often used
as a generator of ROS [60]. When the expression of the
human OGG1 protein was targeted to the mitochondria in
HeLacells,theircapacitytorepairmtDNAoxidativedamages
that are induced by various agents was enhanced, leading
to the increase in cell survival under oxidative stress [61].
To date, few have measured the impact of ageing overall
mtBER capacity in aged skeletal muscle. It was, however,
recently reported that mtBER activity in skeletal muscle is
regulated in an age-dependent manner. Szczesny et al. [62]
investigated age- and tissue-dependent changes in DNA BER
of oxidative lesions in mitochondrial extracts by measuring
single-nucleotide (SN)-BER and long-patch (LP)-BER activ-
ities in several tissues isolated from 4-, 10- and 20-month-
old mice. The mtBER activity was determined by analyzing
the total repair synthesis using duplex oligonucleotides
containing uracil or tetrahydrofuran, speciﬁc lesions for SN-
and LP-BER, respectively. Age-dependent SN-BER activity
was increased in liver, kidney, heart, and quadriceps (fast-
twitch muscle) but not in pectoralis (slow-twitch muscle).
LP-BER activity was also increased in liver, kidney, and heart
but not in quadriceps and pectoralis. APE activity, which is
a key component of BER and is believed to be rate limiting
in the repair of oxidative DNA damage [63], was decreased
in both skeletal muscles with age. Besides mtBER activity,
the expression levels of antioxidant enzymes including man-
ganese superoxide dismutase, copper- and zinc-containing
superoxidedismutase,andcatalasewerealsolowerinskeletal
muscle than in liver, kidney, and heart irrespective of age.
They hypothesize that relatively low levels of mtBER activity
and antioxidant enzymes in skeletal muscle may contribute
to age-associated mitochondrial deﬁciency.
As above mentioned, large deletions in mtDNA are
frequently observed in aged skeletal muscle. It has been
proposed that the generation of these deletions result from
double-strand breaks in mtDNA during repair of damaged
mtDNA rather than during replication [64]. Double-strand
breaks in mtDNA can be repaired by homologous recom-
bination or nonhomologous end-joining mechanisms, as it
occursinthenucleus[16,26].Evidenceforbothhomologous
recombination and nonhomologous end-joining processes
in mammalian mitochondria has been reported. For exam-
ple,mitochondrialproteinextractsfromnormalandimmor-
talized mammalian somatic cells catalyzed homologous
recombination of plasmid DNA substrates [65]. When incu-
bating linearized plasmid DNA with mitochondrial protein
extracts from rodent liver, DNA end-joining activity was
observed [66]. Further, it was recently showed that human
Rad51, which is required for homologous recombination,
localizes also to mitochondria in human cells and could
potentially be involved in organelle double-strand break
repair [67]. However, many other enzymes associated with
these mtDNA repair mechanisms have not been identiﬁed
in the animal mitochondria [68]. It could be speculated that
mitochondrial recombinational DNA repair in mammalian
cells may depend on enzymes involved in other DNA repair
pathways [26]. The signiﬁcance of these mtDNA repair
mechanisms is still a developing area for future investigation.
Thus, although it remains unclear to what extent these
mtDNA repair systems contribute to attenuate age-related
accumulationofmtDNAmutationsinskeletalmuscle,itmay
be due to the decreased capacity for mtDNA repair and/or
insuﬃcient mtDNA repair mechanisms.Journal of Aging Research 5
5. TranscriptionalControl of
MitochondrialBiogenesis
During the last decade or two, there was much progress in
understanding transcriptional regulatory mechanisms gov-
erning mitochondria biogenesis. Mitochondrial biogenesis
is a complex process that requires the synthesis, import,
and incorporation of proteins and lipids to the existing
mitochondrial reticulum as well as replication of the mtDNA
[3]. The mitochondrial proteome comprises approximately
1,500 diﬀerent proteins [69]. More than 98% of the total
protein complement of mitochondria is encoded by the
nuclear genome although the organelle has their own DNA
[18]. To maintain mitochondrial functionality, mitochon-
drial biogenesis requires a coordination of expression of two
genomes and therefore crosstalk between the nucleus and
mitochondria [18]. It is now widely accepted that PGC-
1α plays a central role in a regulatory network governing
the transcriptional control of mitochondrial biogenesis [1,
3, 18, 19]. PGC-1α is known to work in concert with a
wide variety of interacting partners, which are transcription
factors and nuclear receptors [1, 3]. Here we provide
some information on the transcriptional events involved
in mitochondrial biogenesis. For more complete details,
excellent review articles are already available on this subject
[1, 3, 18, 70]. We discuss the underlying mechanisms that
regulate mitochondrial biogenesis in aged skeletal muscle.
PGC-1α w a sd i s c o v e r e di nay e a s tt w o - h y b r i ds c r e e nf o r
brown adipose-speciﬁc factors that interact with the nuclear
receptor PPARγ and are dramatically induced by exposure
to cold in brown fat and skeletal muscle [71]. Subsequently,
twoadditionalPGC-1familymemberswereidentiﬁed,PGC-
1-related coactivator (PRC) [72], and PGC-1β [73]. Gain-
of-function and loss-of-function studies have revealed the
central roles of PGC-1α, PRC, and PGC-1β in mitochon-
drial gene expression and biogenesis. Forced expression of
PGC-1α or PGC-1β in C2C12 cells resulted in increased
mitochondrial biogenesis and oxygen consumption [74, 75].
PRC overexpressing myotubes showed an elevated fatty acid
oxidation and increased expression of mitochondrial genes
[76]. Skeletal muscle-speciﬁc PGC-1α or PGC-1β transgenic
mice exhibited increased mtDNA amount, mitochondrial
content,mitochondrialenzymeactivity,increasedexpression
of mitochondrial genes, and enhanced exercise performance
[77–79]. PGC-1 family coactivators appear to be involved in
a myoﬁber-type conversion. PGC-1α or PRC drives forma-
tion of type I and IIA myoﬁbers [76, 77, 79], which contain
abundant mitochondria [80–82], whereas PGC-1β promotes
formation of type IIX myoﬁbers [78], which are highly
oxidative but have fast twitch characteristics [80–82]. On the
other hand, PGC-1α deﬁciency mice exhibited that mito-
chondrial number and respiratory capacity is diminished
in skeletal muscle, leading to reduced muscle performance
and exercise capacity [83]. Skeletal-muscle-speciﬁc PGC-1α
knockout mice showed decreased expression of mitochon-
drial genes, a shift from oxidative type I and IIa toward
type IIx and IIb myoﬁbers and reduced endurance capacity
[84]. Mice lacking PGC-1β showed a reduced numbers of
mitochondria, decreased respiration function, and decreased
expression of mitochondrial genes [85]. Short hairpin RNA-
mediated silencing of PRC resulted in a severe respiratory
chain deﬁciency associated with the proliferation of aberrant
mitochondria in U20S cells [86]. Recently, mice with total
PGC-1 deﬁciency (PGC-1α−/−βf/f/MLC-Cre mice) in skeletal
muscle have been characterized [87]. PGC-1α−/−βf/f/MLC-Cre
mice exhibited a dramatic reduction in exercise performance
compared to single PGC-1α or PGC-1β-deﬁcient mice and
wild-type mice. Additionally, PGC-1α−/−βf/f/MLC-Cre mice
showed mitochondrial structural derangements consistent
with fusion/ﬁssion and biogenic defects concomitantly with
no reduction of the proportion of oxidative types I and IIa
myoﬁbers [87].
The three coactivators regulate expression of a broad
set of mitochondrial genes and promote mitochondrial bi-
ogenesis [88]. Because these coactivators lack DNA-binding
activity [89, 90], PGC-1 family coactivators exert their
eﬀects through interactions with transcription factors and
nuclear receptors bound to speciﬁc DNA elements in the
promoter region of genes. For example, nuclear respira-
tory factor-1 (NRF-1) and NRF-2 (GA-binding protein;
GABP) were the ﬁrst regulatory factors implicated in the
globalexpressionofmultiplemitochondrialfunctionsinver-
tebrates [19]. Both NRF-1 and NRF-2 link to the tran-
scriptional control of nuclear and mitochondrial genes
involved in OXPHOS, electron transport (complex I–V),
mtDNA transcription/replication, heme biosynthesis, pro-
tein import/assembly, ion channels, shuttles, and translation
[70]. As to mtDNA transcription/replication, NRF-1 or
NRF-2 contribute to expression of nuclear encoded genes
involved in mtDNA transcription/replication machineries
including mitochondrial transcription factor A (TFAM),
mitochondrial transcription factor B1 or B2 (TFB1M or
TFB2M), and mitochondrial RNA polymerase (POL-
RMT), and mitochondrial transcription termination factor
(MTERF),mitochondrialDNAhelicase(TWINKLE),single-
stranded DNA-binding protein (mtSSB), and POLγB[ 91–
93] but not POLγAa n dM T E R F 3[ 93]. Cotransfection
of PGC-1α along with NRF-1 increases the transcrip-
tion of TFAM, a direct regulator of mtDNA replication/
transcription, to a greater extent compared to the expression
of PGC-1α alone [74]. Interestingly, skeletal-muscle-speciﬁc
knockout mice lacking GABPα, the DNA-binding subunit of
GABP, exhibited no overt muscle defects, with normal distri-
bution and appearance of mitochondria [94, 95], suggesting
that GABP might not be essential for muscle mitochondrial
biogenesis and that a compensatory mechanism might exist
to maintain mitochondrial gene expression.
Peroxisome proliferator-activated receptors (PPARs)
were discovered as ligand-activated transcription factors and
are classiﬁed as members of the steroid hormone receptor
superfamily [96]. To date, three related PPAR isoforms have
been identiﬁed including PPARα,P P A R β/δ,a n dP P A R γ
[97]. PPARs act as heterodimers with retinoid X receptors
(RXRs) to regulate a broad set of genes involved in lipid
uptake, storage, and metabolism [98]. Skeletal muscles from
PPARα knockout mice exhibited only minor changes in
fatty acid homeostasis and that neither constitutive nor
inducible mRNA expression of known PPARα target genes is6 Journal of Aging Research
negatively aﬀected by its absence [99]. The highly selective
PPARδ agonist GW742 increased fatty acid oxidation and
induced expression of several lipid regulatory genes in both
primary human satellite cells and L6 myogenic myotubes.
The responses are similar to those elicited by the PPARα
agonistGW647,whereasthePPARγ agonist,GW929,didnot
aﬀect this gene expression [99]. Thus, it is likely that redun-
dancy in the functions of PPARs α and δ as transcriptional
regulators of fatty acid homeostasis and high levels of the
δ-subtype expressed in skeletal muscle can compensate for
deﬁciency of PPARα [99]. Independent expression of either
PPARα or PGC-1 leads to a modest increase in the expres-
sion of medium-chain acyl-CoA dehydrogenase (MCAD),
long-chain acyl-CoA dehydrogenase (LCAD), and carnitine
palmitoyltransferase I (CPT I), whereas coexpression of both
PPARα and PGC-1 leads to a marked coordinate increase
in the expression of the mitochondrial fatty acid oxidation
enzymes in the absence or presence of PPARα ligand [100].
Estrogen-related receptor α (ERRα) is an orphan mem-
ber of the superfamily of nuclear hormone receptors. ERRα
was initially isolated based on its sequence homology to
the estrogen receptor [101] but is not activated by classic
estrogens[102].ERRαhasbeenshowntobeatranscriptional
regulator of MCAD gene [103], which is one of three
nuclearlyencodedproteinsmediatingtheinitialstepinmito-
chondrial β-oxidation of fatty acids [104]. ERRα null mice
showed a decreased fat mass and are resistant to a high-fat-
diet-induced obesity [105]. In C2C12 myogenic cells, ERRα
overexpression accelerated diﬀerentiation with an increased
mitochondrial mass, whereas ERRα antagonist, XCT790
treatment delays myogenesis and resulted in myotubes with
fewer mitochondria and disorganized sarcomeres [106].
Similarly, ERR−/− primary myogenic cells showed delayed
myogenesis, resulting in structurally immature myotubes
with reduced sarcomeric assembly and mitochondrial func-
tion [106]. When ERRα and PGC-1α are cotransfected, they
synergistically enhance the promoter activity of medium-
chain acyl-CoA dehydrogenase gene compared with either
ERRα or PGC-1α [107]. PGC-1β stimulates ERRα-mediated
transcription in a dose-dependent manner by means of the
ERR-responsive element from the MCAD gene promoter
[108].
6.Effects ofAgeingon Mitochondrial
Biogenesis inSkeletal Muscle
Overall, exercise and muscle regeneration promote mito-
chondrial biogenesis, whereas physical inactivity and ageing
decrease it [109–115], suggesting that mitochondrial biogen-
esis is tuned to meet cell-speciﬁc energetic, metabolic, and
signal demands. Although ageing decreases the expression
of mitochondrial genes involved in OXPHOS, electron
transport/ATP synthase, which are encoded in nuclear and
mitochondrial genome in skeletal muscle [50, 116–118], the
molecular mechanisms are not yet well understood. We dis-
cuss several possibilities that may account for the age-related
downregulation of mitochondrial genes in skeletal muscle.
This may be the result of reduced mtDNA copy number
with age. Transcripts corresponding to the mitochondrial
genome are undoubtedly inﬂuenced by decreasing mtDNA
copy number [118, 119]. Consequently, the expression of the
proteins encoded by mitochondrial genome would logically
be expected to be inﬂuenced by the availability of the mRNA
template. Indeed, substantial mtDNA depletion occurred
with decreased expression in mitochondria-encoded COX
subunits I and III in aged skeletal muscles [119]. Such a
decline paralleled reduced COX enzyme activity [119]. More
important, however, is that COX transcript levels relative to
mtDNA were comparable in young and old animals. This
indicates that reduced mtDNA copy number has no major
eﬀects on mitochondrial encoded transcript levels [119].
Thus, reduced mtDNA availability may not be a limiting
factorofmitochondrialgeneexpressioninagedskeletalmus-
cle. It seems unlikely that age-related reductions of mtDNA
may be due to downregulation of several factors essential for
mtDNA replication. There was no eﬀect of age on expression
of TFAM, NRF-1, POLγA, POLγB, RNase mitochondrial
RNA processing (RNase MRP), POLRMT, and mtSSB tran-
script levels [50, 116–118], suggesting the possibility that
mtDNA replication machinery may be preserved during the
process of ageing. Additionally, TFAM protein expression
was moderately increased in skeletal muscle of aged animals
[56]. This may be indicative of a compensatory attempt
to attenuate the decay in mitochondrial enzyme activity
and functional mtDNA content in senescent skeletal muscle
[120].
Decreased mitochondrial biogenesis with age may be
related to the changes in expression of PGC-1 family
coactivators. For example, PGC-1β expression was reduced
in skeletal muscle from elderly human [121]. We observed
decreased expression level of PGC-1β transcript in mouse
skeletal muscle in an age-dependent manner (our unpub-
lished data). The expression of PGC-1β is investigated
in an experimental murine model of accelerated ageing,
senescence-accelerated prone mice (SAMP) and senescence-
accelerated resistant mice (SAMR) [122]. SAMR series
normally age, whereas SAMP series exhibit an accelerated
aging with a number of common characteristics, such as
a moderate-to-severe degree of loss of activity, hair loss
and lack of glossiness, periophthalmic lesions, increased lor-
dokyphosis, and early death [123]. Consistent with naturally
aged human and mouse, SAMP showed a decrease in PGC-
1β expression compared to SAMR. In agreement with the
proposed role of PGC-1β function as a coactivator of ERRα,
the expression of the ERRα target gene MCAD was strongly
suppressed in SAMP with the reduction in ERRα DNA-
binding activity [122]. Additionally, decreased PPAR DNA-
binding activity, possibly through enhanced transcriptional
repressor, chicken ovalbumin upstream promoter transcrip-
tion factor II (COUP-TF-II), was observed in SAMP. The
enhanced expression of COUP-TF-II has shown to reduce
the expression of the PPARα-target gene, acyl-CoA oxidase,
which cods for a key enzyme involved in β-oxidation [124].
Therefore, fatty acid oxidation is reduced or impaired in
SAMP. Unlike PGC-1β, conﬂicting results were observed in
previous studies with respect to age-related changes in PGC-
1α expression. COX activity was decreased concomitantlyJournal of Aging Research 7
with decreased expression of PGC-1α protein in old (36-
months-old) compared to young (6-months-old) rats [56].
Similarly, decreased expression of PGC-1α mRNA or protein
was observed in skeletal muscle from old human [121],
mouse [125]a n dr a t[ 126]. In contrast, PGC-1α mRNA or
protein expression remained unchanged with age in human,
rat, and mouse skeletal muscles despite a downregulation of
mitochondrial genes [117, 118, 122, 127]. We also observed
no change in PGC-1α mRNA expression among young,
middle-aged, and old animals (our unpublished data).
These data suggest that age-related decreased mitochondrial
biogenesis may not necessarily parallel decreased expression
level of PGC-1α.
Several lines of evidence suggest that the activity of
PGC-1α is regulated by a variety of posttranslational modiﬁ-
cations, which have assumed to be an important mechanism
that could regulate PGC-1α transcriptional activity [3, 18].
Multiple signaling pathways have been shown to regulate
PGC-1α activity. For example, PGC-1α has a very short
half-life of about 2-3 hours [128], and the mitogen-activated
protein kinase (MAPK) p38 phosphorylates, stabilizes
PGC-1α protein and enhances PGC-1α activity [129, 130].
AMP-activated protein kinase (AMPK), which is activated
by an increase in intracellular AMP/ATP ratio, has been
involved in mitochondrial biogenesis [131]. It was proposed
that direct phosphorylations of the PGC-1α protein at Thr
177 and Ser 538 are required for the PGC-1α-dependent
induction of the PGC-1α promoter [132]. AMPK can be
activatedchemicallywithAICAR(5 -aminoimidazole-4-car-
boxamide-1-β-D-ribofuranoside), which is taken up by cells
and phosphorylated by adenosine kinase to form ZMP
(5 -aminoimidazole-4-carboxamide-1-β-D-ribofuranoside
monophosphate) that mimics the eﬀect of AMP [133].
Treatment of mice with AICAR increased expression of mi-
tochondrial proteins and enhanced exercise endurance
[134]. AMPK activation via AICAR treatment in C2C12
cells induced PGC-1α mRNA expression and transcription-
ally activates the PGC-1α promoter [135]. When rodents
were treated with AICAR, it promoted mitochondrial bio-
genesis and fatty acid oxidation [136, 137]. Knockout
mice lacking both AMPK β1a n dβ2 isoforms in skel-
etal muscle had reduced mitochondrial content and
showed drastically impaired capacity for tread-mill run-
ning [138]. When transgenic mice expressing a dom-
inant-negative mutant of AMPK in muscle were treated
with β-guanidinopropionic acid (β-GPA), a creatine analog,
which leads to similar reductions in the intramuscular ATP/
AMP ratio and phosphocreatine concentrations, they exhib-
ited abrogated β-GPA-induced increases in the mitochon-
drial content [139]. Interestingly, p38 MAPK and AMPK
activation levels in skeletal muscle under steady-state condi-
tions were generally similar between young and old animals,
despite the age-related variations in mitochondrial volume
[140]. However, the activation of AMPK or p38 MAPK in
response to AICAR, exercise, and muscle contraction was
blunted in aged skeletal muscle [140, 141]. Therefore, their
potential role in regulating PGC-1α transcriptional activity
may be impaired in aged skeletal muscle. The signaling
deﬁcit may, in part at least, account for reduced PGC-1α-
mediated mitochondrial biogenesis during the process of
ageing. Besides phosphorylation, it has been shown that
PGC-1α activity is potentiated by arginine methylation
by arginine methyltransferase 1 (PRMT1) [142]. PRMT1
methylates PGC-1α in the C-terminal region and enhances
its transcriptional activity. Short interfering RNA-mediated
silencing of PRMT1 caused decreases in the expression of
PGC-1α-induced cytochrome c and ERRα genes. Since few
studies report a possible role of PRMT1 in aged skeletal
muscle, it remains unclear to what extent PRMT1-mediated
PGC-1α activity contributes to mitochondrial biogenesis.
PGC-1α activity is also modulated by its acetylation state
by the deacetylase, SIRT1 (silent mating type-information
regulation 2 homolog 1) and the acetyltransferase, GCN5
(generalcontrolnonrepressedprotein5)[143].SIRT1,which
is a NAD+-dependent deacetylase, deacetylates PGC-1α pro-
tein and activates PGC-1α activity [143]. AMPK acts as the
primeinitialsensorthattranslateslownutrientavailabilityor
increased energy demand into SIRT1-dependent deacetyla-
tion of PGC-1α [144]. SIRT1 was bound to PGC-1α-targeted
genepromotersandrelativeoccupancyatthesesitescouldbe
signiﬁcantly enhanced when overexpressing SIRT1 in C2C12
myotubes [145]. The SIRT1 activator SRT1720 also led to
ad e c r e a s ei nP G C - 1 α acetylation, and an increase in the
expression of PGC-1α targets involved in fatty acid oxidation
in mouse skeletal muscle [146]. Conversely, knockdown
of SIRT1 or the SIRT1 inhibitor, nicotinamide induced
PGC-1α protein acetylation, decreases expression of PGC-1α
target genes, and reduced fatty acid oxidation in myotubes
[145]. In aged skeletal muscle, SIRT activity was decreased
possibly though a decrease in NAD+ content, which could
be due to reduced expression of NAD+ biosynthetic enzyme,
NAMPT (nicotinamide phosphoribosyltransferase) [147].
Thus, age-related decreased SIRT1 activity may aﬀect PGC-
1α-mediated mitochondrial biogenesis. It should be noted,
however, that overexpression of SIRT1 in rodent skeletal
muscle was shown to downregulate several genes involved
in mitochondrial biogenesis despite increased SIRT1 activity
[148]. Recently, mice lacking skeletal muscle SIRT1 activity
did not impede exercise-induced deacetylation of PGC-
1α and mitochondrial biogenesis [149]. These results sug-
gest that the role of SIRT1 in the activation of PGC-1α
mediated transcription appears to be more complex than
originally hypothesized. On the other hand, PGC-1α is
directly acetylated by GCN5, resulting in a transcriptionally
inactive protein that relocalizes from promoter regions to
nuclear foci [150]. Knockdown of SRC-3 (steroid receptor
coactivator-3) in C2C12 cells reduced the expression of
GCN5, decreased the acetylation of PGC-1α, and increased
the expression of PGC-1α-regulated mitochondrial genes
[151]. PGC-1β is also acetylated by GCN5. GCN5 strongly
interacted with PGC-1β and repressed its transcriptional
activity associated with transcription factors such as ERRα
and NRF-1 [152]. Besides GCN5, two well-established
histone acetyltransferases, SRC-1 and CREB-binding pro-
tein (CBP)/p300, which have been shown to be strong
enhancers of PGC-1α activity without acetylating PGC-1α
by them [89]. This contribution may be not expected since8 Journal of Aging Research
SRC-1 and CBP/p300 proteins were decreased with age in rat
motoneurons of the spinal nucleus of the bulbocavernosus
[153].
PGC-1α activity may be negatively regulated by several
factors. Akt/PKB directly phosphorylates PGC-1α and pre-
vents the recruitment of PGC-1α to the cognate promoters,
impairing its ability to promote gluconeogenesis and fatty
acid oxidation [154]. Age-related hyperphosphorylation of
Akt at Thr 308 and Ser 473 were observed in rat skeletal
muscle [155]. Phosphorylation of these two residues is
necessary for full activation of Akt kinase activity [156].
It should be noted, however, that age-related Akt hyper-
phosphorylation did not result in increased phosphorylation
of the Akt downstream molecules such as glycogen synthase
kinase3β (GSK3β)[ 155]. GSK3β also targets PGC-1α for
nuclear proteasomal degradation and regulates PGC-1α
activity [157]. In aged skeletal muscle, phosphorylation
level of GSK3β on Ser 9, which is necessary for GSK3β
inactivation [158], is decreased with age [159], suggesting
that GSK3β activity is increased. Thus, age-related change
in Akt-GSK3β signaling may aﬀect PGC-1α turnover and
thereby mitochondrial biogenesis. The human receptor-
interactingprotein140(RIP140)wasidentiﬁedasacoactiva-
tor for a chimeric estrogen receptor [160]. RIP140 is highly
expressed in metabolic tissues such as skeletal muscle [161].
RIP140 has been proposed as suppressor of mitochondrial
biogenesis and oxidative metabolism in mammalian cells
[162]. The possible role of RIP140 has been conﬁrmed
by genetically modiﬁed mice. RIP140 null mice exhibited
an increase in size and quantity of mitochondria, amount
of mtDNA, and number of oxidative ﬁbers in fast-twitch
muscle concomitantly with upregulation of genes involved
in OXPHOS, fatty-acid oxidation, TCA cycle, glycolysis, and
triglyceride synthesis, whereas RIP140 in transgenic mice
showed a decreased oxidative capacity activity [163]. RIP140
interacts directly with PGC-1α and suppresses its activity
[164]. However, RIP140 has also been observed to have
ag r e a t e re ﬀect on PGC-1β than PGC-1α in adipocytes,
probably because of the relatively low levels of PGC-1α
found in these cells [163]. This may be the case with
myogenic cells. C2C12 myogenic cells normally express
PGC-1α at very low level, whereas PGC-1β and PRC were
readilydetectableundersteady-stateconditions[72,92,165].
Thus, RIP140 suppresses PGC-1β and PRC activity more
than PGC-1α, leading to decreased mitochondrial biogenesis
in aged skeletal muscle. Interestingly, ability of RIP140 to
repress some mitochondrial genes depends on endogeneous
ERRα [162], suggesting that the same transcription factor
can mediate positive and negative eﬀects on mitochondrial
biogenesis depending on the cellular context. PGC-1α also
contains a negative regulatory domain that attenuates its
transcriptional activity, and the p160 myb binding protein
(p160MBP) acts as a repressor of PGC-1α by binding to this
regulatory region. This interaction is further regulated by
p38 MAPK, which phosphorylates the inhibitory domain of
PGC-1α,e ﬃciently disrupting p160MBP-binding and releas-
ing PGC-1α from its inhibition [166]. Adenoviral expression
of p160MBP in myoblasts strongly reduced PGC-1α’s ability
to stimulate mitochondrial respiration and the expression
of the genes of the electron transport system [166]. These
negative regulators(RIP140andp160MBP) maymodulate the
activity of PGC-1 family coactivators, leading to decreased
mitochondrial biogenesis observed in aged skeletal muscle.
There are, however, few reports on expression of these
negative regulators in aged skeletal muscle.
7. Conclusion
This paper provides the current knowledge about the molec-
ular mechanisms responsible for age-associated mitochon-
drial deﬁciency in skeletal muscle. Several cellular mech-
anisms would be expected to contribute to mitochondrial
deﬁciency in skeletal muscle. Among them, accumulation
of somatic mtDNA mutations appears to correlate with
respiratory chain deﬁciency in aged skeletal muscle. How-
ever, the extent to which low level mutation (<1%) can be
functionallyrelevantinageingisasubjectofcontroversy.The
capacity of mitochondrial biogenesis also may be required
in maintaining energy production and cellular homeostasis
because damaged mitochondria are eliminated during the
process of ageing. There is increasing evidence that PGC-
1α plays a central role in a regulatory network governing
the transcriptional control of mitochondrial biogenesis in
concert with other transcription factors and nuclear recep-
tors. Intriguingly, it has been demonstrated that transgenic
MCK-PGC-1α mice have preserved mitochondrial function
as well as neuromuscular junctions and muscle integrity
during ageing [125]. This suggests that modulation of PGC-
1α levels in skeletal muscle will oﬀer eﬀective therapeutic
potential for prevention and treatment of a group of age-
related disorders.
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